# Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

> **NCT00330564** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Von Hippel-Lindau Syndrome
- Renal Cell Carcinoma
- Hemangioblastoma

## Interventions

- **DRUG:** SU011248

## Key facts

- **NCT ID:** NCT00330564
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Slow accrual.
- **Last updated:** 2024-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00330564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00330564, "Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00330564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*